[Perioperative treatment of muscle-invasive bladder cancer : Current treatment concepts].

Günter Niegisch, Camilla Grunewald

Abstract readReviewEnglish Abstract

In one paragraph

Review in Urologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Günter NiegischBereich Konservative Urologische Onkologie, Medizinische Fakultät und Universitätsklinikum Düsseldorf, Klinik für Urologie, Moorenstr. 5, 40225, Düsseldorf, Deutschland. uro-onkologie@med.uni-duesseldorf.de.

Camilla GrunewaldBereich Konservative Urologische Onkologie, Medizinische Fakultät und Universitätsklinikum Düsseldorf, Klinik für Urologie, Moorenstr. 5, 40225, Düsseldorf, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Perioperative systemic treatment is a central component of the multimodal treatment of muscle-invasive bladder cancer (MIBC) and significantly improves the prognosis of patients. Current guidelines recommend an interdisciplinary tumor board for treatment planning, with cisplatin-based chemotherapy, checkpoint inhibitors used alone, sequentially or in combination as well as antibody-drug conjugates combined with checkpoint inhibitors being employed. Recent data demonstrate that the combination of gemcitabine, cisplatin, and durvalumab extends event-free and overall survival. Relative contraindications should be individually weighed up to enable as many patients as possible to receive adequate treatment. In particular, combination therapies involving antibody-drug conjugates are expected to gain importance in perioperative systemic treatment in the future.

Indexed as

Perioperative CareUrinary Bladder NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCisplatinCombined Modality TherapyCystectomyDeoxycytidineGemcitabineHumansImmune Checkpoint InhibitorsNeoplasm InvasivenessCisplatinDeoxycytidineGemcitabineImmune Checkpoint InhibitorsCheckpoint inhibitorCisplatinPerioperative chemotherapyRadical cystectomyUrothelial cancer

Identifiers

PMID42536143

DOI10.1007/s00120-026-02900-w

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.